UK-based clinical stage biopharmaceutical company Hemogenyx Pharmaceuticals plc (LON:HEMO) said on Tuesday that it has signed a non-binding Letter of Intent (LOI) with Estonian cell therapy company Cellin Technologies to pursue commercialisation of its HG-CT-1 CAR-T therapy in Estonia.

The therapy targets relapsed or refractory acute myeloid leukaemia (AML). This collaboration represents the first potential near-term revenue opportunity for HG-CT-1.

The partnership aims to leverage Estonia's hospital exemption pathway, which was updated in April 2025 to allow broader use of advanced therapy medicinal products prior to full market authorisation. The framework permits treatment of unlimited patients, reimbursement via the Estonian National Health Fund, and the generation of real-world clinical data alongside Hemogenyx's ongoing Phase I trial.

Under the agreement, Hemogenyx will retain full ownership of HG-CT-1 intellectual property, data, and regulatory rights, while Cellin will serve as the local partner. Cellin's role includes manufacturing, regulatory support, securing permits, and coordinating treatment delivery through physicians.

The LOI establishes a framework for collaboration, with binding terms to be finalised in future definitive agreements.